Keywords: Bayer, Onyx Pharma, Nexavar, Ph III, Lung cancer, NSCLC

Bayer and Onyx' Nexavar fails in Ph III lung cancer study

Article | 23 May 2012

Print This

There was disappointment for German drug major Bayer (BAYB: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX), when the companies reported ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in